145 related articles for article (PubMed ID: 10809428)
1. Role of antigenemia assay in the early diagnosis and treatment of CMV infection in renal transplant patients.
Chiaramonte S; Pellizzer G; Rassu M; Dissegna D; Bragantiini L; Zuccarotto D; La Greca G
Clin Nephrol; 2000 Apr; 53(4):suppl 10-2. PubMed ID: 10809428
[TBL] [Abstract][Full Text] [Related]
2. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
[TBL] [Abstract][Full Text] [Related]
3. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
4. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
[TBL] [Abstract][Full Text] [Related]
5. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
7. Quantitative PCR in the diagnosis of CMV infection and in the monitoring of viral load during the antiviral treatment in renal transplant patients.
Piiparinen H; Helanterä I; Lappalainen M; Suni J; Koskinen P; Grönhagen-Riska C; Lautenschlager I
J Med Virol; 2005 Jul; 76(3):367-72. PubMed ID: 15902704
[TBL] [Abstract][Full Text] [Related]
8. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
9. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
[TBL] [Abstract][Full Text] [Related]
10. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
Murray BM; Subramaniam S
Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program.
Rossini F; Terruzzi E; Cammarota S; Morini F; Fumagalli M; Verga L; Elli E; Verga M; Miccolis I; Parma M; Pogliani EM
Transpl Infect Dis; 2005; 7(3-4):122-5. PubMed ID: 16390400
[TBL] [Abstract][Full Text] [Related]
12. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality.
Bacigalupo A; Tedone E; Sanna MA; Moro F; Van Lint MT; Grazi G; Balestreri M; Frassoni F; Occhini D; Gualandi F
Haematologica; 1992; 77(6):507-13. PubMed ID: 1337746
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
[TBL] [Abstract][Full Text] [Related]
14. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infection in renal transplant recipients.
Carstens J; Andersen HK; Spencer E; Madsen M
Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
[TBL] [Abstract][Full Text] [Related]
16. [Primary cytomegalovirus infection after combined cadaveric transplantation of the liver and kidney].
Slavicek J; Puretić Z; Glavas-Boras S; Smalcelj R; Barisić I; Vuković J; Seso-Simić D; Slavicek V; Humar I; Kes P
Acta Med Croatica; 2003; 57(1):87-90. PubMed ID: 12876872
[TBL] [Abstract][Full Text] [Related]
17. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus antigenemia assay or PCR can be used to monitor ganciclovir treatment in bone marrow transplant recipients.
Vlieger AM; Boland GJ; Jiwa NM; de Weger RA; Willemze R; de Gast GC; Falkenburg JH
Bone Marrow Transplant; 1992 Apr; 9(4):247-53. PubMed ID: 1318141
[TBL] [Abstract][Full Text] [Related]
20. Is combined pretransplantation seropositivity of kidney transplant recipients for cytomegalovirus antigens (pp150 and pp28) a predictor for protection against infection?
Essa S; Pacsa A; Said T; Nampoory MR; Raghupathy R; Johny KV; Al-Nakib W; Al-Mosawy M
Med Princ Pract; 2008; 17(1):66-70. PubMed ID: 18059104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]